# A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

> **NCT07010419** · PHASE3 · RECRUITING · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 338 (estimated)

## Conditions studied

- NSCLC
- Adjuvant Treatment

## Interventions

- **DRUG:** Firmonertinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07010419
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-28
- **Primary completion:** 2028-10-31
- **Final completion:** 2032-04-30
- **Target enrollment:** 338 (ESTIMATED)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07010419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07010419, "A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07010419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*